This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Philip R. Liebson, MD; Greg Grandits, MS; Richard H. Grimm, Jr, MD, PhD
Rush-Presbyterian-St Luke's Medical Center Chicago, Ill

JAMA. 1996;276(7):526-527.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—We read with great interest the results of the meta-analysis by Dr Schmieder and colleagues.¹ In their "Comment" section, the authors indicated that the Treatment of Mild Hypertension Study (TOMHS)² was not included in the meta-analysis, among other studies, because it did not fulfill 1 of the 12 inclusion criteria, namely, that the primary goal of the study was to analyze the effects of antihypertensive compounds on left ventricular hypertrophy.

We feel that this is a weak reason for exclusion of a study (and possibly other studies) that were randomized, doubleblinded and also placebo-controlled (not an absolute criterion for the meta-analysis). Change in left ventricular mass was 1 of several end points in TOMHS. In fact, a criterion for inclusion in the TOMHS study was an adequate echocardiographic study. The total number of participants in TOMHS in the 4 drug treatment groups corresponding to the . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?